Browsing ICR Divisions by author "Garcia-Murillas, Isaac"
Now showing items 21-29 of 29
-
Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC).
Lee, JY; Cutts, RJ; White, I; Augustin, Y; Garcia-Murillas, I; et al. (FRONTIERS MEDIA SA, 2020-04-17)Background: Following chemo-radiotherapy (CRT) for human papilloma virus positive (HPV+) anal squamous cell carcinoma (ASCC), detection of residual/recurrent disease is challenging. Patients frequently undergo unnecessary ... -
PIK3CA mutation enrichment and quantitation from blood and tissue.
Keraite, I; Alvarez-Garcia, V; Garcia-Murillas, I; Beaney, M; Turner, NC; et al. (NATURE PORTFOLIO, 2020-10-13)PIK3CA is one of the two most frequently mutated genes in breast cancers, occurring in 30-40% of cases. Four frequent 'hotspot' PIK3CA mutations (E542K, E545K, H1047R and H1047L) account for 80-90% of all PIK3CA mutations ... -
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens, C; O'Leary, B; Kilburn, L; Hrebien, S; Garcia-Murillas, I; et al. (2016-09)Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that ... -
Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma.
Lee, JY; Garcia-Murillas, I; Cutts, RJ; De Castro, DG; Grove, L; et al. (SPRINGERNATURE, 2017-09-05)BACKGROUND: Following chemo-radiotherapy (CCRT) for human papilloma virus positive (HPV+) locally advanced head and neck cancer, patients frequently undergo unnecessary neck dissection (ND) and/or repeated biopsies for ... -
Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer.
Hrebien, S; O'Leary, B; Beaney, M; Schiavon, G; Fribbens, C; et al. (PUBLIC LIBRARY SCIENCE, 2016-10-19)Circulating tumor DNA (ctDNA) analysis has the potential to allow non-invasive analysis of tumor mutations in advanced cancer. In this study we assessed the reproducibility of digital PCR (dPCR) assays of circulating tumor ... -
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
Turner, NC; Swift, C; Jenkins, B; Kilburn, L; Coakley, M; et al. (ELSEVIER, 2022-11-21)BACKGROUND: Post-treatment detection of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer (TNBC) patients predicts high risk of relapse. c-TRAK TN assessed the utility of prospective ctDNA ... -
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
O'Leary, B; Cutts, RJ; Liu, Y; Hrebien, S; Huang, X; et al. (AMER ASSOC CANCER RESEARCH, 2018-11-01)CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence ... -
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer.
Barry, P; Vatsiou, A; Spiteri, I; Nichol, D; Cresswell, GD; et al. (SPRINGER, 2018-02-01)Purpose: The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge ... -
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Pascual, J; Lim, JSJ; Macpherson, IR; Armstrong, AC; Ring, A; et al. (AMER ASSOC CANCER RESEARCH, 2021-01-01)Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K inhibitors synergize in PIK3CA-mutant ER-positive HER2-negative breast cancer models. We conducted a phase Ib trial investigating the safety and efficacy of doublet CDK4/6 ...